Wild-type p53 epitope naturally processed and presented by an HLA-B haplotype on human breast carcinoma cells

Clinical Cancer Research

Volumn 5, Issue 8, 1999, Pages 2089-2093

  Papadopoulos, Kyriakos P ^a   Hesdorffer, Charles S ^a   Suciu Foca, Nicole ^b   Hibshoosh, Hanina ^b   Harris, Paul E ^b  

^a Columbia University ^*  (United States)

^b New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN P53;

AMINO ACID SEQUENCE; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CARCINOMA CELL; DOWN REGULATION; EPITOPE MAPPING; HAPLOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HLA SYSTEM; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

ADENOCARCINOMA; AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; BREAST NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EPITOPES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HAPLOTYPES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-B ANTIGENS; HUMANS; IMMUNOPHENOTYPING; PEPTIDE FRAGMENTS; SEQUENCE ANALYSIS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032771492     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Archer, S. G., Eliopoulos, A., Spandidos, D., Barnes, D., Ellis, I. O., Blamey, R. W., Nicholson, R. I., and Robertson, J. F. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br. J. Cancer, 72: 1259-1266, 1995.
2. Bukholm, I. K., Berner, J. M., Nesland, J. M., and Borresen-Dale, A. L. Expression of cyclin Ds in relation to p53 status in human breast carcinomas. Virchows Arch., 433: 223-228, 1998.
3. Maki, C. G., Huibregtse, J. M., and Howley, P. M. In vivo ubiquitination and proteasome-mediated degradation of p53 (1). Cancer Res., 56: 2649-2654, 1996.
4. Ciechanover, A., DiGiuseppe, J. A., Bercovich, B., Orian, A., Richter, J. D., Schwartz, A. L., and Brodeur, G. M. Degradation of nuclear oncoproteins by the ubiquitin system in vitro. Proc. Natl. Acad. Sci. USA, 88: 139-143, 1991.
5. Apostolopoulos, V., Karanikas, V., Haurum, J. S., and McKenzie, I. F. Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J. Immunol., 159: 5211-5218, 1997.
6. Alters, S. E., Gadea, J. R., and Philip, R. Immunotherapy of cancer. Generation of CEA-specific CTL using CEA peptide-pulsed dendritic cells. Adv. Exp. Med. Biol., 417: 519-524, 1997.
7. Disis, M. L., Smith, J. W., Murphy, A. E., Chen, W., and Cheever, M. A. In vitro generation of human cytolytic T cells specific for peptides derived from the HER-2/neu protooncogene protein. Cancer Res., 54: 1071-1076, 1994.
8. DeLeo, A. B. p53-based immunotherapy of cancer. Crit. Rev. Immunol., 18: 29-35, 1998.
9. Anton, L. C., Snyder, H. L., Bennink, J. R., Vinitsky, A., Orlowski, M., Porgador, A., and Yewdell, J. W. Dissociation of proteasomal degradation of biosynthesized viral proteins from generation of MHC class I-associated antigenic peptides. J. Immunol., 160: 4859-4868, 1998.
10. Harris, P. E., Maffei, A., Colovai, A. I., Kinne, J., Tugulea, S., and Suciu-Foca, N. Predominant HLA-class II bound self-peptides of a hematopoietic progenitor cell line are derived from intracellular proteins. Blood, 87: 5104-5112, 1996.
11. Harris, P. E., Lupu, F., Hong, B., Reed, E. F., and Suciu-Foca, N. Differentiation-stage specific self-peptides bound by major histocompatibility complex class I molecules. J. Exp. Med., 177: 783-790, 1993.
12. Griffioen, M., Steegenga, W. T., Ouwerkerk, I. J., Peltenburg, L. T., Jochemsen, A. G., and Schrier, P. I. Repression of the minimal HLA-B promoter by c-myc and p53 occurs through independent mechanisms. Mol. Immunol., 35: 829-835, 1998.
13. Redondo, M., Concha, A., Ruiz-Cabello, F., Morell, M., Esteban, F., Talavera, P., and Garrido, F. Class I major histocompatibility complex antigens and tumor ploidy in breast and bronchogenic carcinomas. Cancer Detect. Prev., 21: 22-28, 1997.
14. Chia, D., Sugich, L., Acalimovich, A., and Chan, H. Caucasian US normal. In: D. Gjertson and P. Terasaki (eds.), HLA 1998, pp. 254. Lenexa: American Society of Histocompatability and Immunogenetics, 1998.
15. McCormack, J., and Osowski, L. Black US normal. In: D. Gjertson and P. Terasaki (eds.), HLA 1998, pp. 233. Lenexa: American Society of Histocompatability and Immunogenetics, 1998.
16. Sherman, L. A., Theobald, M., Morgan, D., Hernandez, J., Bacik, I., Yewdell, J., Bennink, J., and Biggs, J. Strategies for tumor elimination by cytotoxic T lymphocytes. Crit. Rev. Immunol., 18: 47-54, 1998.
17. Theobald, M., Ruppert, T., Kuckelkorn, U., Hernandez, J., Haussler, A., Ferreira, E. A., Liewer, U., Biggs, J., Levine, A. J., Huber, C., Koszinowski, U. H., Kloetzel, P. M., and Sherman, L. A. The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J. Exp. Med., 188: 1017-1028, 1998.
18. Gnjatic, S., Bressac-de Paillerets, B., Guillet, J. G., and Choppin, J. Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules. Eur. J. Immunol., 25: 1638-1642, 1995.
19. Nijman, H. W., Van der Burg, S. H., Vierboom, M. P., Houbiers, J. G., Kast, W. M., and Melief, C. J. p53, a potential target for tumor-directed T cells. Immunol. Lett., 40: 171-178, 1994.
20. Stuber, G., Leder, G. H., Storkus, W. T., Lotze, M. T., Modrow, S., Szekely, L., Wolf, H., Klein, E., Karre, K., and Klein, G. Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay. Eur. J. Immunol., 24: 765-768, 1994.
21. Zeh, H. J., 3rd, Leder, G. H., Lotze, M. T., Salter, R. D., Tector, M., Stuber, G., Modrow, S., and Storkus, W. J. Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2. Hum. Immunol., 39: 79-86, 1994.
22. Zhang, Q. J., Gavioli, R., Klein, G., and Masucci, M. G. An HLA-A11-specific motif in nonamer peptides derived from viral and cellular proteins. Proc. Natl. Acad. Sci. USA, 90: 2217-2221, 1993.
23. Houbiers, J. G., Nijman, H. W., van der Burg, S. H., Drijfhout, J. W., Kenemans, P., van de Velde, C. J., Brand, A., Momburg, F., Kast, W. M., and Melief, C. J. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol., 23: 2072-2077, 1993.
24. Nijman, H. W., Houbiers, J. G., van der Burg, S. H., Vierboom, M. P., Kenemans, P., Kast, W. M., and Melief, C. J. Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides. J. Immunother., 14: 121-126, 1993.
25. Ropke, M., Regner, M., and Claesson, M. H. T cell-mediated cytotoxicity against p53-protein derived peptides in bulk and limiting dilution cultures of healthy donors. Scand. J. Immunol., 42: 98-103, 1995.
26. Vierboom, M. P., Nijman, H. W., Offringa, R., van der Voort, E. I., van Hall, T., van den Broek, L., Fleuren, G. J., Kenemans, P., Kast, W. M., and Melief, C. J. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J. Exp. Med., 186: 695-704, 1997.
27. Theobald, M., Biggs, J., Dittmer, D., Levine, A. J., and Sherman, L. A. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA, 92: 11993-11997, 1995.
28. Ropke, M., Hald, J., Guldberg, P., Zeuthen, J., Norgaard, L., Fugger, L., Svejgaard, A., Van der Burg, S., Nijman, H. W., Melief, C. J., and Claesson, M. H. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc. Natl. Acad. Sci. USA, 93: 14704-14707, 1996.
29. Gnjatic, S., Cai, Z., Viguier, M., Chouaib, S., Guillet, J. G., and Choppin, J. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. J. Immunol., 160: 328-333, 1998.
30. Maffei, A., Papadopoulos, K., and Harris, P. E. MHC class I antigen processing pathways. Hum. Immunol., 54: 91-103, 1997.
31. Theobald, M., Biggs, J., Hernandez, J., Lustgarten, J., Labadie, C., and Sherman, L. A. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J. Exp. Med., 185: 833-841, 1997.
32. Parker, K. C., Bednarek, M. A., and Coligan, J. E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol., 152: 163-175, 1994.
33. Alexander-Miller, M. A., Leggatt, G. R., Sarin, A., and Berzofsky, J. A. Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J. Exp. Med., 184: 485-492, 1996.
34. Alexander-Miller, M. A., Leggatt, G. R., and Berzofsky, J. A. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA, 93: 4102-4107, 1996.
35. Fujita, H., Senju, S., Yokomizo, H., Saya, H., Ogawa, M., Matsushita, S., and Nishimura, Y. Evidence that HLA class II-restricted human CD4+ T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms. Eur. J. Immunol., 28: 305-316, 1998.